Navigation Links
UNC receives NIH grant to develop and test new drugs to block HIV infection
Date:7/18/2011

CHAPEL HILL, N.C. Scientists at the University of North Carolina at Chapel Hill schools of medicine and pharmacy have been awarded a $3 million federal grant to develop and test a new generation of treatments aimed at preventing sexual transmission of HIV to uninfected individuals. This remains the most common cause of HIV infection worldwide.

The new NIAID award is entitled Next Generation Pre-Exposure Prophylaxis, or PrEP. "This project combines the strengths of four outstanding investigators with highly complementary skills, at UNC and our industrial partner, Merck," said J. Victor Garcia-Martinez, PhD, the project's principal investigator and professor of medicine, and a member of UNC's Center for Infectious Diseases and Center for AIDS Research.

Project collaborators with Garcia-Martinez are Angela Kashuba, PharmD, associate professor, and Russell Mumper, PhD, McNeill Distinguished Professor, both in the UNC Eshelman School of Pharmacy, and Daria Hazuda, PhD, at Merck Research Laboratories. Merck will not receive federal funding from this award. "We will address issues of fundamental importance to the next generation of PrEP agents," Garcia-Martinez said.

The new grant from the National Institute of Allergy and Infectious Diseases (NIAID) follows the July 11 announcement of a $32 million award from the agency to UNC to lead scientists from eight other universities in the search for ways to purge hidden HIV from the immune systems of infected patients taking antiretroviral therapy.

"This new award serves as further testament to the outstanding environment for conducting state-of-the-art AIDS research at UNC and will strengthen the close ties between our programs in medicine and pharmacy," Garcia-Martinez said.

According to Garcia-Martinez, significant progress has been made in developing measures to prevent HIV infection, but recent results of clinical trials reveal that "the level of protection observed is suboptimal and that there is significant room for further improvement."

The UNC scientist also points out that most of the trials that are ongoing now involve drugs that are used for treatment, and to which there is drug-resistance in many parts of the world. "If you use for prevention the same drug you use for treatment, you may encounter situations where drug-resistant viruses might emerge. So we need to be ahead of the virus and to start working on HIV therapies that will be available for the next generation, which is the aim of this NIH initiative."

The new project will explore candidate drugs, experimental compounds, not yet tested in people. Preclinical experiments will be conducted in humanized BLT mice. The "BLT" name is derived from the fact that these designer mice are created one at a time by introducing human bone marrow, liver and thymus tissues into animals without an immune system of their own.

Humanized BLT mice have a fully functioning human immune system and can be infected with HIV in the same manner as humans. The laboratory of Garcia-Martinez has pioneered the development of this humanized mouse model. "Prevention of sexual transmission of HIV is urgently needed," he said.


'/>"/>

Contact: Les Lang
llang@med.unc.edu
919-966-9366
University of North Carolina School of Medicine
Source:Eurekalert  

Related medicine news :

1. UCSF receives $112 million to help translate science into cures
2. Wayne State University engineering student receives American Tinnitus Association award
3. Allina receives NIH grant to study real world usage of integrative therapies
4. Brookhaven Labs Joanna Fowler receives Distinguished Women in Chemistry Award
5. UH Cancer Center receives $3.58 million gift for mesothelioma research
6. UC Riverside botanist receives high honor from Howard Hughes Medical Institute
7. Illinois professor John A. Rogers receives $500,000 Lemelson-MIT Prize
8. Penn State receives $27.3 million NIH grant
9. University of Houston researcher receives grant to study water pollutants
10. Rhode Island Hospital fellow receives funding to support research in myocardial perfusion
11. Pioneering stem cell bandage receives approval for clinical trial
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UNC receives NIH grant to develop and test new drugs to block HIV infection
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: